Invests in categories: BiotechDevelopmentDrugHealthcareHealthTechMedtechPharmaceuticalsProductResearchTechnology
Sofinnova deploys human and financial capital to turn dreams into drugs. We are a clinical-stage biopharmaceutical venture capital firm with approximately $2B in assets under management and committed capital.
News
317
Portfolio
108
Persons
39
Mentions
146
Employees: 11-50
Investment Type: Venture Capital
Investment Stage: Series A; Series B; Series C; Series E
Portfolio 108
Show more
Persons 39
| Date | First Name | Last Name | Title | Location | |||
| - | Justin | Lee, PhD | Analyst, P... | - | - | - | |
| - | Merdad | Parsey, MD... | Executive ... | - | - | - | |
| - | Perry | Nisen, MD,... | Executive ... | - | - | - | |
| - | Laurel | Russell | New York O... | - | - | - | |
| - | Jim | Healy, MD,... | Managing P... | - | - | - | |
| - | James | Healy, MD,... | Managing P... | - | - | - | |
| - | Surin | Kim | Financial ... | - | - | - | |
| - | Gina | Baker | Compliance... | - | - | - | |
| - | Jenn | Symmons | Events Man... | - | - | - | |
| - | Lesley | Weber | Executive ... | - | - | - | |
| - | Calvin | Sternick | Analyst, P... | - | - | - | |
| - | Kathy | Du | Vice Presi... | - | - | - | |
| - | Maha | Radhakrish... | Executive ... | - | - | - | |
| - | Ricardo | Grieshaber... | Venture Pa... | - | - | - | |
| - | Jakob | Dupont, MD | Executive ... | - | - | - | |
| - | Smita | Chowdhri | Controller... | - | - | - | |
| - | Nick | Lenard | Analyst, P... | - | - | - | |
| - | Tiffany | Davis | Director o... | - | - | - | |
| - | David | Kabakoff, ... | Executive ... | - | - | - | |
| - | Amanda | Phillips | Executive ... | - | - | - | |
| - | Anastasia | Voevodin, ... | Analyst, P... | - | - | - | |
| - | James | Brody | Chief Comp... | - | - | - | |
| - | Katrin | Viller | Vice Presi... | - | - | - | |
| - | Daniel | Ni, MD, Ph... | Analyst, P... | - | - | - | |
| - | Naomi | Pacalin, P... | Associate,... | - | - | - | |
| - | Aneal | Tenjarla | Partner, A... | - | - | - | |
| - | Seth | Filbrun | Associate,... | - | - | - | |
| - | Maha | Katabi, Ph... | General Pa... | - | - | - | |
| - | Rachel | Urrutia | Finance an... | - | - | - | |
| - | Jonathan | Vu, MD | Analyst, P... | - | - | - | |
| - | Chris | Carpenter,... | Executive ... | - | - | - | |
| - | Eric | Delbridge,... | General Pa... | - | - | - | |
| - | Jonathan | Leff, MD | Executive ... | - | - | - | |
| - | Kasey | Olson | Boston Off... | - | - | - | |
| - | Lars | Ekman, MD,... | Executive ... | - | - | - | |
| - | Paul | Chang | Analyst, P... | - | - | - | |
| - | John | Barrett, P... | Senior Ana... | - | - | - | |
| - | Josie | Kastelic | Menlo Park... | - | - | - | |
| - | Eric | Hsu, PhD | Analyst, P... | - | - | - |
Show more
News 317
Show more
Mentions in press and media 146
| Date | Title | Description |
| 17.09.2026 | Innvierte destina en julio y agosto más de 11 millones de euros a nueve nuevas coinversiones en capital riesgo | Desde enero de 2026 el CDTI Innovación, a través de Innvierte, ha cerrado operaciones de coinversión en 38 empresas con un compromiso de 85,9 millones de euros y ha comprometido inversiones en 10 vehículos de inversión con un compromiso de ... |
| 10.08.2026 | Expedition Therapeutics Closes $115 Million Series B | SAN FRANCISCO, CA, Expedition Therapeutics, a clinical-stage biotechnology company developing novel oral small molecule therapies for inflammatory and respiratory diseases, announced the closing of an oversubscribed $115 million Series B f... |
| 09.08.2026 | Expedition Therapeutics Lands $115M Series B | SAN FRANCISCO, CA, Expedition Therapeutics has announced the closing of an oversubscribed $115 million Series B financing round. >> Click here for more funding data on Expedition Therapeutics >> To export Expedition Therapeutic... |
| 05.08.2026 | Expedition Therapeutics Raises $115M in Series B Funding | Expedition Therapeutics, a San Francisco, CA-based clinical-stage biotechnology platform, raised $115M in Series B financing. The round was led by General Atlantic with participation from RA Capital, Vivo Capital, Sofinnova Investments, Nov... |
| 03.08.2026 | Claris Biotherapeutics Raises $118M in Series B Funding | Claris Biotherapeutics, Inc., a Jersey City, NJ-based biopharmaceutical company developing therapies for sight-threatening conditions, raised $118M in Series B financing. The round was led by Samsara Biocapital and Catalio Capital Managemen... |
| 09.06.2026 | City Therapeutics Raises $99.5M in Series B Funding | City Therapeutics, Inc., a Cambridge, MA-based biopharmaceutical company developing RNA interference (RNAi)-based medicines, raised $99.5M in Series B funding. The round was led by Viking Global Investors and Sofinnova Investments with part... |
| 29.04.2026 | Coultreon Biopharma Raises $125 Million Series A to Advance Oral Autoimmune Therapy | Coultreon Biopharma, a Belgium-based biotechnology company formerly known as Onco3R Therapeutics, has closed an oversubscribed 125 million dollar Series A financing round to advance its immunology pipeline. The round was led by Sofinnova In... |
| 13.03.2026 | May Health Secures $11.7M for PCOS Infertility Breakthrough | May Health, a medical device innovator, closed an $11.7 million funding round. New investor Nexpring Health led the investment. Existing partners Sofinnova Partners, Bpifrance, and Trill Impact also participated. This capital fuels the REBA... |
| 11.03.2026 | May Health Raises $11.7M in Funding | May Health, a Menlo Park, CA-based developer of medical devices for polycystic ovary syndrome (PCOS), raised $11.7M in funding. The round was led by new investor Nexpring Health, with participation from existing shareholders Sofinnova Partn... |
| 10.03.2026 | May Health: $11.7 Million Raised To Advance PCOS-Related Infertility Treatment Technology | May Health, a medical device company focused on expanding treatment options for women living with polycystic ovary syndrome (PCOS), announced that it has raised €10 million (about $11.7 million) in new funding. The round included participat... |
| 03.03.2026 | Jolt Capital: Former FORVIA CEO Patrick Koller Joins As Operating Partner | Jolt Capital has appointed Patrick Koller, former CEO of FORVIA, as an operating partner, adding a veteran European automotive executive to its deeptech-focused private equity platform. Koller brings 29 years of experience in the automotive... |
| 27.02.2026 | Verley Secures €32M to Revolutionize Protein Market with Precision Fermentation | Verley, a French foodtech innovator, secured €32 million in Series A funding. The company leverages precision fermentation to produce functional whey proteins. These next-generation ingredients, like beta-lactoglobulin, address rising globa... |
| 25.02.2026 | Verley: €32 Million Series A Raised To Scale Precision-Fermented Whey Protein Ingredients | Verley, a Lyon-based food and nutrition ingredient company developing high-performance whey proteins through precision fermentation, has secured an oversubscribed €32 million Series A round, including non-dilutive funding, four years after ... |
| 24.02.2026 | Precision fermentation startup Verley raises $38m Series A as BLG unlocks new segment of protein market | – Verley—one of a handful of players making a whey protein called beta-lactoglobulin (BLG) via precision fermentation—has raised €32 million ($38 million) as it gears up to enter the US market later this year. – The round includes €25 milli... |
| 24.02.2026 | Verley closes €32M Series A to advance next-generation functional whey ingredients | French foodtech startup Verley has raised €32 million in a Series A financing round, only four years after its inception. Verley develops functional whey protein ingredients, more precisely beta-lactoglobulin (BLG), designed to deliver the ... |
| 24.02.2026 | With high-protein nutrition now mainstream, Lyon’s Verley raises €32 million to expand production | Verley, a French nutrition-focused ingredient company developing high-performance whey proteins through precision fermentation, has secured an oversubscribed €32 million Series A financing round – four years after its inception. The round w... |
| 15.02.2026 | Neurent Medical Secures €62.5 Million to Propel NEUROMARK Expansion | Neurent Medical secured a substantial €62.5 million Series C funding round. This capital accelerates commercial growth for its NEUROMARK System. The innovative technology targets chronic rhinitis, offering durable relief. It employs impedan... |
| 12.02.2026 | Neurent Medical: €62.5 Million Series C Raised For Expanding NEUROMARK Commercially | Neurent Medical, a Galway, Ireland based medical technology company focused on chronic inflammatory sinonasal diseases, has closed an oversubscribed €62.5 million ($74 million) Series C financing to accelerate the commercial expansion of it... |
| 12.02.2026 | Chronic rhinitis solution NEUROMARK secures €62.5 million as Irish startup Neurent Medical closes Series C | Galway-based Neurent Medical, the company behind NEUROMARK, a minimally invasive solution to treat chronic rhinitis, today announced the successful close of its oversubscribed Series C financing, raising €62.5 million ($74 million) to drive... |
| 02.02.2026 | Tenpoint Therapeutics Secures $235M, Prepares YUVEZZI Launch for Presbyopia | Tenpoint Therapeutics secured $235 million in new capital. This robust funding fuels the impending launch of YUVEZZI. YUVEZZI is an FDA-approved, first-of-its-kind dual-agent eye drop. It targets presbyopia, a widespread aging vision condit... |
| 30.01.2026 | Tenpoint Therapeutics: $235 Million Raised To Launch YUVEZZI Presbyopia Eye Drop | Tenpoint Therapeutics has secured $235 million in new funding to support the planned commercialization of its presbyopia treatment, YUVEZZI. The company said the capital combines an $85 million Series B preferred stock financing and a $150 ... |
| 29.01.2026 | Tenpoint Therapeutics Raises $235M Through Series B and Credit Facility | Tenpoint Therapeutics, Ltd., a London, UK and Seattle, WA-based provider of vision rejuvenation treatments for the aging eye, raised $235m through a Series B stock financing and a credit facility. The company raised $85m in Series B financi... |
| 29.01.2026 | Tenpoint Therapeutics: $235 Million Raised To Launch Dual Agent Presbyopia Eye Drop YUVEZZI | Tenpoint Therapeutics said it has secured $235 million in new capital, combining an $85 million Series B preferred stock financing with a $150 million senior secured term loan facility, as the company prepares to commercialize its newly app... |
| 10.01.2026 | BrightHeart: €11 Million Series A Raised To Expand Prenatal Ultrasound AI Platform | BrightHeart, a Paris-based developer of AI software for prenatal ultrasound, said it has closed an €11 million Series A financing to fund U.S. commercialization, broader European expansion and continued product development for its B-Right A... |
| 08.01.2026 | BrightHeart bags €11M to expand FDA-cleared AI ultrasound platform across the US and Europe | Medtech BrightHeart, a developer of solutions for prenatal ultrasound, today announced it has raised €11 million Series A financing round. The round was co-led by Odyssée Venture and GO Capital, with participation from the Mussallem CHD All... |
| 08.01.2026 | BrightHeart Raises €11M in Series A Funding | BrightHeart, a Paris, France-based company which specializes in artificial intelligence (AI) solutions for prenatal ultrasound, raised €11M in Series A funding. The round was led by Odyssée Venture and GO Capital, with participation from th... |
| 28.12.2025 | Aeovian Pharmaceuticals Secures $55M Series B for Groundbreaking Epilepsy Treatment | Aeovian Pharmaceuticals secured a significant $55 million Series B funding. This pivotal investment propels its lead candidate, AV078, into a Phase 2 study. AV078 is a first-in-class CNS-penetrant selective mTORC1 inhibitor. It targets seve... |
| 27.12.2025 | Aeovian Pharmaceuticals: $55 Million Series B Raised To Advance AV078 For Tuberous Sclerosis Complex-Related Refractory Epilepsy | Aeovian Pharmaceuticals, a clinical-stage biopharmaceutical company based in Berkeley, California, has closed an oversubscribed $55 million Series B financing to support completion of a Phase 2 proof-of-concept study for its lead candidate,... |
| 19.12.2025 | These new venture capital funds have dry powder to invest in Swiss startups in 2026 | 19.12.2025 16:15, João Guerra After years of tight capital and cautious investors, 2026 is shaping up as a turning point for founders. Venturelab data shows fundraising momentum is accelerating, and optimism is rising across Europe with 125... |
| 16.12.2025 | Aeovian Pharmaceuticals Raises $55M in Funding | Aeovian Pharmaceuticals, a Berkeley, CA-based clinical-stage biopharmaceutical company, raised $55M in funding. The round was led by Luma Group and CTI Life Sciences Fund, with participation from Foresite Capital, SymBiosis, the TSC Allianc... |
| 15.12.2025 | DISCO Pharmaceuticals: €36 Million Seed Funding Raised And Mark Manfredi Named As CEO | DISCO Pharmaceuticals has appointed biotech executive Mark Manfredi, Ph.D., as chief executive officer and completed the final close of a €36 million seed financing round to advance its pipeline of surfaceome-targeted drug candidates for ha... |
| 12.10.2025 | Star Therapeutics: $125 Million Series D Raised For Developing Antibodies For Bleeding Disorders | Star Therapeutics, an innovative clinical-stage biotechnology company, is dedicated to discovering and developing cutting-edge antibodies aimed at treating bleeding disorders and other medical conditions. The company recently announced the ... |
| 09.10.2025 | Expedition resupplies for phase 2 COPD voyage with $165M series A | Expedition Therapeutics is gearing up for a phase 2 trek with a $165 million series A that closed Oct. 9. The new funding will fuel the Bay Area biotech’s DPP1 inhibitor EXPD-101 as it ventures into a study in patients with chronic obstruct... |
| 09.10.2025 | Expedition Therapeutics: $165 Million Series A Raised For Advancing DPP1 Inhibitor For COPD | Expedition Therapeutics, a biotechnology company dedicated to developing therapies for novel inflammatory and respiratory diseases, has closed an oversubscribed and upsized Series A financing round, raising $165 million. This financing roun... |
| 07.08.2025 | Artbio Secures $132M to Accelerate Precision Cancer Therapies | Artbio, a pioneering radiopharmaceutical firm, locked in $132 million Series B funding. This investment drives AB001, its innovative alpha radioligand therapy for metastatic castration-resistant prostate cancer, toward Phase II clinical tri... |
| 07.08.2025 | ARTBIO: $132 Million Series B Raised For New Class Of Alpha Radioligand Therapies | ARTBIO, a clinical-stage radiopharmaceutical company, is focused on developing alpha radioligand therapies (ARTs) for various types of cancer. The company has secured $132 million in Series B financing, co-led by new investors Sofinnova Inv... |
| 14.04.2025 | Atsena Therapeutics: $150 Million (Series C) Closed To Advance Ocular Gene Therapy Programs | Atsena Therapeutics – a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness – recently announced the closing of an oversubscribed $150 million Series C fnuding.... |
| 04.04.2025 | Atsena Therapeutics Raises $150M in Series C Financing | Atsena Therapeutics, a Durham, NC-based clinical-stage gene therapy company, raised $150M in Series C funding. The round was led by Bain Capital’s Life Sciences team, with participation from an additional new investor, Wellington Management... |
| 02.04.2025 | Atsena raises $150M for ocular gene therapies with Bain, Sofinnova in tow | Atsena Therapeutics has raised $150 million in an oversubscribed series C financing, with hopes that the funds can carry the biotech’s gene therapy designed to reverse or prevent blindness through a potential market approval. The funding ro... |
| 19.03.2025 | Weatherford Capital Closes Fund II | Weatherford Capital, a Tampa, FL-based private investment firm, closed its Fund II, at $300M. Led by Will Weatherford, Managing Partner, Weatherford Capital is a family-owned private investment firm that prioritizes businesses across the te... |
| 07.03.2025 | €450M to drive green data infrastructure, the next startup hub, and key trends and investment in February | This week we tracked more than 70 tech funding deals worth over €1.3 billion, and over 5 exits, M&A transactions, rumours, and related news stories across Europe. This week we also released Tech.eu Pulse, a compact version of our monthl... |
| 01.03.2025 | European Innovation Council Fuels DeepTech Revolution with Major Investments | In the heart of Europe, innovation is blossoming. The European Innovation Council (EIC) is leading the charge, injecting substantial funds into groundbreaking technologies. Two companies, QDI Systems and NanoPhoria, are at the forefront of ... |
| 26.02.2025 | NanoPhoria: €17.5 Million Awarded For Non-Viral Drug Delivery Platform | NanoPhoria, a pre-clinical stage biotech company developing a versatile and non-viral drug delivery platform based on inorganic nanoparticles with a lead product for heart failure treatment, announces the investment commitment of €17.5 mill... |
| 13.02.2025 | Latent Labs: The New Frontier in Programmable Biology | In the world of biotechnology, a new player has emerged, ready to rewrite the rules. Latent Labs, a London-based startup, has burst onto the scene with a staggering $50 million in funding. This infusion of capital is not just a number; it’s... |
| 13.02.2025 | AI pioneer Dr Simon Kohl's Latent Labs emerges from stealth, raising $50M for programmable biology | AI foundation model builder Latent Labs today emerged from stealth with $50 million in total funding to accelerate their progress in programmable biology. The company was founded by Dr Simon Kohl, previously a co-lead of DeepMind’s protein ... |
| 14.01.2025 | Bioptimus brings its funding to $76M for the GPT of biology | AI foundation model company Bioptimus has raised a further $41 million cash injection, bringing its funding to $76 million. Bioptimus is redefining how we approach biological research by addressing a longstanding issue: the siloed nature of... |
| 27.12.2024 | So können VCs den Impact von Startups messen | Gemeinsam mit führenden europäischen VC-Fonds wie ETF Partners, Sofinnova Partners, Astanor und SET Ventures haben wir bei FoodLabs als Teil der Coalition for Impact in Venture das Handbuch “Impact Accountability in Venture Capital: A Ready... |
| 14.12.2024 | The Rise of nChroma Bio: A New Dawn in Genetic Medicine | In the world of biotechnology, mergers and funding are the lifeblood of innovation. Recently, two companies, Chroma Medicine and Nvelop Therapeutics, joined forces to create nChroma Bio. This new entity is set to redefine the landscape of g... |
| 12.12.2024 | Chroma Medicine and Nvelop Therapeutics Unite to Form nChroma Bio and Raises $75M | Biotechnology companies Chroma Medicine (Boston, MA) and Nvelop Therapeutics (Cambridge, MA) announced their merger and subsequent launch of nChroma Bio to expand the R&D of the genetic medicines sector. Concurrent with the merger, nChr... |
| 11.12.2024 | EQT Life Sciences Leads Series B Extension in Noema Pharma, Raising Total Series B Financing to CHF 130 million | EQT Life Sciences Leads Series B Extension in Noema Pharma, Raising Total Series B Financing to CHF 130 million Wed, Dec 11, 2024 09:30 CET Report this content Proceeds will be used to enable key late-stage clinical trial readouts for asset... |
| 11.12.2024 | Noema Pharma extends Series B funding to CHF 130 million | EQT Life Sciences’ LSP 7 fund has invested in Noema Pharma. The clinical-stage biotech company headquartered in Basel is developing a pipeline of first-in-disease therapeutics that address central nervous system (CNS) disorders. The Series... |
| 22.10.2024 | Seaport Therapeutics: $225 Million (Series B) Raised To Advance Novel Neuropsychiatric Medicines | Seaport Therapeutics—a clinical-stage biopharmaceutical company advancing novel neuropsychiatric medicines with a proven strategy and team—announced the closing of an oversubscribed $225 million Series B financing round. General Atlantic, a... |
| 11.10.2024 | Investment Climate Podcast: Giuseppe Scionti of NovaMeat | In this podcast series, Alex Shandrovsky interviews investors about benchmarks for funding alt proteins in 2024 and uncovers the investment playbooks of successful climate tech CEOs and leading VCs. Podcast Host Alex Shandrovksy is a strate... |
| 23.09.2024 | Arzeda: Protein Design Company Closes $38 Million In Funding | Protein design company Arzeda announced it has raised $38 million in funding. This funding round includes new investments from Sofinnova Partners, Fall Line Capital, Sucden Ventures, Silver Blue, and the venture arm of W.L. Gore & Assoc... |
| 18.09.2024 | Arzeda Raises $38M in Funding | Arzeda, a Seattle, WA-based protein design company,raised $38M in funding. The round was led by Sofinnova Partners, Fall Line Capital, Sucden Ventures, Silver Blue, and the venture arm of W.L. Gore & Associates. Previous investors also ... |
| 12.09.2024 | Novameat's €17.4M Funding: A Leap into the Future of Plant-Based Meat | In the bustling heart of Barcelona, a culinary revolution is brewing. Novameat, a pioneering plant-based meat startup, has secured €17.4 million in a Series A funding round. This investment, led by Sofinnova Partners and Forbion via its Bio... |
| 12.09.2024 | Novameat Closes $19.2M Series A Round, Revamps Plant-Based Shredded Beef with Better Texture | 5 Mins Read Spain’s Novameat has attracted €17.4M in a Series A funding round to expand its plant-based meat range based on MicroForce technology, starting with a revamped shredded beef offering. Catalan food tech startup Novameat has recei... |
| 12.09.2024 | Novameat Secures €17.4M in Oversubscribed Round, Launches Improved Shredded Plant-Based Beef | Barcelona’s Novameat, a B2B company specializing in different cuts of plant-based chicken, beef, and turkey, announces it has raised €17.4 million in an oversubscribed Series A round led by Sofinnova Partners and Forbion via its BioEconomy ... |
| 12.09.2024 | Novameat raises $19.2m to expand next-gen plant-based meat texturizing tech: ‘We have a clear path to profitability’ | Barcelona-based plant-based meat startup Novameat has raised a €17.4m ($19.2 million) series A round. Sofinnova and Forbion BioEconomy led the round, supported by existing investors Praesidium, Unovis Asset Management and Rubio Impact Ventu... |
| 27.07.2024 | Micropep's Leap: Transforming Agriculture with Micropeptide Innovation | In the world of agriculture, innovation is the lifeblood. It’s the spark that ignites change. Micropep Technologies is a shining example of this principle. Recently, the company secured $29 million in Series B funding, pushing its total fun... |
| 25.07.2024 | Micropep: Micropeptide Technology Leader Raises $29 Million | Micropep Technologies – a global leader in micropeptide technology, announced today a $29 million Series B funding round along with its proprietary discovery platform Krisalix. This funding round was led by Zebra Impact Ventures, and BPI Gr... |
| 16.07.2024 | EQT Life Sciences invests in Asceneuron, a neurodegeneration therapeutics company, as part of USD 100 million Series C financing round | EQT Life Sciences invests in Asceneuron, a neurodegeneration therapeutics company, as part of USD 100 million Series C financing round Tue, Jul 16, 2024 09:15 CET Report this content EQT Life Sciences has invested in Asceneuron’s oversubscr... |
| 28.05.2024 | Asahi Kasei announces a recommended public cash offer to the shareholders and ADS holders of Calliditas | Asahi Kasei announces a recommended public cash offer to the shareholders and ADS holders of Calliditas Tue, May 28, 2024 08:15 CET Report this content THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO BUY OR THE SOLICITATION OF AN OFFER T... |
| 12.03.2024 | Nvidia стала делать ставку на все технологии, связанные с ИИ. За год компания инвестировала в 30 стартапов $1,55 млрд... | Последний год для производителя чипов Nvidia стал поворотным, поскольку он превзошел все ожидания и к концу февраля достиг рыночной капитализации более $2 трлн. Это сделало компанию крупнейшей по рыночной капитализации после Microsoft и App... |
| 11.03.2024 | It's not just chips. Nvidia is betting on other tech that could be impacted by AI. | Tech It's not just chips. Nvidia is betting on other tech that could be impacted by AI. Lloyd Lee 2024-03-11T03:42:26Z Share icon An curved arrow pointing right. Share Facebook Icon The letter F. Facebook Email icon An envelope. It indicate... |
| 27.10.2023 | Sofinnova Partners raises $200m for maiden digital medicine fund | - |
| 01.04.2020 | Sofinnova Investments Adds Jonathan Leff as Executive Partner | Sofinnova Investments, a Menlo Park, CA-based clinical stage biopharmaceutical investment firm, added Jonathan Leff, M.D. to the investment team as an Executive Partner. With more than 25 years of clinical development experience in the biot... |
| 31.03.2020 | Sofinnova Investments Promotes Two | Sofinnova Investments, a Menlo Park, CA-based clinical stage biopharmaceutical investment firm, promoted Maha Katabi, PhD, CFA to General Partner and Sarah Bhagat, PhD to Partner. Maha Katabi, PhD, CFA who joined Sofinnova in April 2019, ha... |
| 18.03.2020 | Sofinnova Investments Adds Jonathan Leff as Executive Partner | Sofinnova Investments, a clinical stage biopharmaceutical investment firm, added Jonathan Leff, M.D. to the investment team as an Executive Partner. With more than 25 years of clinical development experience in the biotechnology and pharmac... |
| 17.10.2019 | Sofinnova Partners raises $370.3 million for its early-stage healthcare fund to invest in healthtech and life sciences startups | Investments in healthcare and Life Sciences startups continue to soar. Now, the sector is boosted by today’s announcement from Sofinnova Partners, a leading European venture capital firm based in Paris, London and Milan and specialized in L... |
| 22.04.2019 | Sofinnova Investments Adds Maha Katabi as a Partner | Maha Katabi, PhD. Sofinnova Investments, a Menlo Park, Calif.-based clinical stage biopharmaceutical investment firm, added Maha Katabi, PhD. to the investment team as a Partner. Maha Katabi, PhD., is an experienced investor in biopharma co... |
| 28.03.2019 | Polyneuron Raises CHF22.5 M for Autoimune Diseases | |
| 02.08.2017 | NEA Joins $67M Series C for Amplyx Pharmaceuticals | Amplyx Pharmaceuticals, a company developing novel antifungal agents for life-threatening fungal infections, today announced that it has raised $67 million through a Series C financing led by Sofinnova Venture Partners and including other n... |
| 23.05.2017 | Term Sheet — Tuesday, May 23 | FALSE START Good morning – today’s column didn’t come together in time. Back tomorrow! • Can China Save Hollywood? Paid Content What you need to know about growing cyberattacks From ExtraHop • The Fortune 100 Companies Doing the Most to Sto... |
| 23.03.2017 | Ysios Capital lidera una ronda de $30M en BioClin Therapeutics junto con Sofinnova Ventures | 23/03/2017 Nota de prensa YSIOS LIDERA UNA RONDA DE $30 MILLONES EN BIOCLIN THERAPEUTICS JUNTO CON SOFINNVA VENTURES. La entidad de capital riesgo (venture capital)Ysios Capital, ha liderado la ronda de financiación de serie B – por un i... |
| 16.03.2017 | Agtech Funding Sheet: Leonardo DiCaprio invests in LoveTheWild, ProducePay raises $7m | LoveTheWild, the Boulder-based frozen seafood brand that only sources farmed fish, has closed an undisclosed Series A round of funding with Leonardo DiCaprio and seafood-focused venture capital fund Aqua-Spark. The fund invested $2.5 millio... |
| 16.03.2017 | Agtech Funding Sheet: Leonardo DiCaprio Invests in LoveTheWild, ProducePay Raises $7m Series A, more | LoveTheWild, the Boulder-based frozen seafood brand that only sources farmed fish, has closed an undisclosed Series A round of funding with Leonardo DiCaprio and seafood-focused venture capital fund Aqua-Spark. The fund invested $2.5 millio... |
| 09.03.2017 | Belgian Startup Using Llama Antibodies for Biopesticides Increases Series B to $11.6m | AgroSavfe, a Belgian agro-biotech company that is developing a new generation of biopesticides, has increased its Series B financing round to $11.6 million. The bulk of the additional investment was provided by the Paris-based venture capit... |
| 22.01.2017 | France, The New Wave of Venture Capital Funds | France is emerging as one of the most active European countries in terms of venture capital investment activity. A trend confirmed by the latest official data available. During the first half of 2016, €5.5 billion were invested in more than... |
| 28.11.2016 | Galera Therapeutics Receives $15M from Sofinnova Ventures | Galera Therapeutics, Inc., a Malvern, PA-based clinical-stage biotechnology company developing new treatments for cancer patients, received $15m in funding from new backer Sofinnova Ventures. The investment brought the total amount raised i... |
| 17.10.2016 | Sofinnova Closes Latest Venture Capital Fund, at $650M | Sofinnova, a Menlo Park, CA-based biotech-focused investment firm, closed its latest fund, at $650M. Sofinnova Venture Partners X, whose initial target was $550M, is the fourth fund to follow the firm’s strategy of investing in mid and late... |
| 26.08.2016 | Sofinnova Ventures has raised $595M for its largest fund to date | The company’s strategy of investing in late-stage private companies has found some receptive buyers for those businesses, demonstrated by acquisitions of its portfolio companies from the likes of Teva, Shire and Pfizer. And yet, it has also... |
| 08.04.2016 | MedDay raises $38.5M to kick off U.S. clinical trials for multiple sclerosis | “The SPI2 study is expected to confirm, in a large North American population, the results of our prior European MS-SPI study and will further advance MedDay in the field of progressive MS worldwide,” CEO Frédéric Sedel said in a statement. ... |
| 24.03.2016 | Daily funding roundup - March 24, 2016 | Mesophere received $73.5M investment; Iterum Therapeutics secured $40M; Lagou completed Series C Malaysia-based Nuren Group, a company that runs a number of women-dedicated content and e-commerce websites, raised $2 million in a Series A ro... |
| 06.01.2016 | Daily funding roundup - January 6, 2016 | Flatiron Health bagged $175M; NextCure, Inc. raised $67M; AirCloset received $8M funding Ossia, a Bellevue, WA-based maker of a wireless power technology, received a strategic investment from Molex, LLC, a global manufacturer of electronic ... |
| 31.12.2015 | HealthQuest raising new $175M medtech fund | From the first fund, Healthquest Partners has made seven investments in medtech startups, including arthroscopy diagnostics maker Trice Medical, specialty drug health IT startup VirMedica, and First Aid Shot Therapy – a consumer-facing star... |
| 23.11.2015 | Daily funding roundup - November 23, 2015 | ColorChip raised $25M; Quizlet secured $12M; Sportpursuit received $14.4M funding South Korean apartment cleaning service WaHome has received $1 million in a seed investment from Sparklabs Global Ventures, Mashup Angels, Fast Track Asia and... |
| 18.11.2015 | Daily funding roundup - November 18, 2015 | Ola bagged $500M; Joyable raised $8M; Test IO landed $5M TestCloud, a self-service crowdtesting platform for app and Web developers, has a new name and a big new round of funding, the company announced on Wednesday, all to facilitate a big ... |
| 18.11.2015 | First Aid Shot Therapy® (F.A.S.T) Completes $24 million Series C Financing | BURLINGAME, Calif., Nov. 18, 2015 /PRNewswire/ — First Aid Shot Therapy® (F.A.S.T.), a consumer healthcare company focused on over-the-counter (OTC) medicine in liquid shot form (40ml / 1.35oz.), announced today that it has completed a Seri... |
| 13.10.2015 | Daily funding roundup - October 13, 2015 | EverString raised $65M; Audentes Therapeutics bagged $65M; SteelBrick received $48M Predictive marketing company EverString has raised $65 million, in what is the largest round ever for an AI company. Lightspeed Venture Partners led the Com... |
| 29.09.2015 | Asceneuron raises CHF 30 million | |
| 12.08.2015 | Checkmate nets $20M to develop drug that boosts checkpoint inhibitor efficacy | Checkmate Pharmaceuticals operates on the idea that checkpoint inhibitor therapies would be much more effective if they were combined with an agent that could stimulate a person’s immune response. So, on top of the new financing, it’s also ... |
| 12.08.2015 | Daily funding roundup - August 12, 2015 | PokitDoc closed $34M; Infogain secured $63M; Soothe raised $10.6M If there's a service that I often book with little time in advance, it's getting a massage. It's hard to predict when you're neck or back will ache, and when you have a free ... |
| 21.07.2015 | Daily funding roundup - July 21, 2015 | Bright.md raises $3.5M; Medallia bagged $150M; BrightBytes landed $33M Bright.md, which makes software that enables communication between doctors and patients, closed a $3.5 million Series A funding round. Oregon Angel Fund led the round, w... |
| 06.04.2015 | Natera Raises $55.5M | Natera, Inc., a San Carlos, Calif.-based genetic testing company, raised approximately $55.5m in funding. The round was led by Sofinnova Ventures with participation from Capital Research and Management, Franklin Templeton Investments, Jenni... |
| 02.10.2014 | Aclaris Therapeutics Closes $21M Series B Financing | Aclaris Therapeutics, Inc., a Malvern, Pennsylvania-based specialty pharmaceutical company, closed on a $21m Series B financing. Backers included existing investors Vivo Ventures, Fidelity Biosciences and Sofinnova Ventures. Founded in Augu... |
| 19.08.2014 | HealthQuest Capital raises $110M for healthcare investments | HealthQuest Capital is looking to make some moves healthcare with its newly raised $110 million fund, looking for unmet needs in medical devices, diagnostics and information technology. The Sofinnova Ventures-backed investment group garnere... |
| 23.07.2014 | Sofinnova Ventures Closes Ninth Fund at $500M | Sofinnova Ventures, a Menlo Park based investment firm dedicated to life science, closed its ninth fund at $500m. Led by Srini Akkaraju, MD, PhD, Jim Healy, MD, PhD, Anand Mehra, MD, Mike Powell, PhD, Lars Ekman, MD, PhD, David Kabakoff, Ph... |
| 10.07.2014 | Sofinnova appears to be bulking up a healthcare venture fund to $110 million | Sofinnova Ventures has a robust active portfolio. Some of its more notable funding rounds include participation in a $72.8 million Series B round with Spark Therapeutics, a $55 million C round with Coherus Bio Sciences and a $50 million rou... |
| 11.02.2014 | First Aid Shot Therapy Completes Series B Financing Round | First Aid Shot Therapy (F.A.S.T.), a Burlingame, California-based consumer healthcare company, completed its Series B financing round. The round – of undisclosed amount – was co-led by Sofinnova Ventures and Redmile Group with participation... |
Show more